NEW
Stock Screener with Intrinsic Value
Alnylam Pharmaceuticals, Inc. (ALNY)
Last Price$238.0(1.1%)
Market Cap$30.1B
LTM Free Cash Flow
$16.1M
Reverse DCF (Implied FCF growth)
62.8%
3Y Free Cash Flow CAGR
N/A
LTM Revenue
$2,094.8M
Reverse DCF (Implied Revenue growth)
29.8%
at normalized FCF margin 6.9%
3Y Revenue CAGR
40.9%
ALNY Reverse DCF Model
Crunching data... Almost there!
Best stock ideas on the market right now
With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.
ALNY Free Cash Flow
Crunching data... Almost there!
ALNY Growth
Crunching data... Almost there!
ALNY vs Peer Set: Reverse DCF comparison
Crunching data... Almost there!
Explore more intrinsic value tools hub for ALNY
DCF value calculator
Peter Lynch Fair Value
Discount rate
Relative Value
Earnings growth model
Peter Lynch charts
Margin of safety
Intrinsic Value
Earnings Power Value
Ben Graham Fair Value
Loved by
investors
worldwide
investors
worldwide
10K+
Investors
use our platform
#1
Top value investing hub
with all necessary tools
1K+
Experienced investors
in our community
4.9
Average rating across
all rating platforms
FAQ
What is Alnylam Pharmaceuticals, Inc. Reverse DCF (discounted cash flow) valuation?
As of Sep 30, 2024, Alnylam Pharmaceuticals, Inc.'s Reverse Discounted Cash Flow (DCF) valuation estimates its Free Cash Flow growth at 62.8%.
What is Alnylam Pharmaceuticals, Inc. WACC?
As of Sep 30, 2024, Alnylam Pharmaceuticals, Inc.'s Weighted Average Cost of Capital (WACC) is approximately 6.6%.
What is Alnylam Pharmaceuticals, Inc. Free Cash Flow?
As of Sep 30, 2024, Alnylam Pharmaceuticals, Inc.'s Free Cash Flow is $16.1M.